BioMotiv Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Cleveland, OH USA
Total Funding:$435.1M
Industry:Biotech
Founded:2012
Lead Investor(s):Charles River Laboratories International Inc

Industry Ranking

Estimated Revenue & Financials

  • BioMotiv's estimated annual revenue is currently $8.4M per year.
  • BioMotiv received $63.0M in venture funding in August 2016.
  • BioMotiv's estimated revenue per employee is $155,000
  • BioMotiv's total funding is $435.1M.

Employee Data

  • BioMotiv has 54 Employees.
  • BioMotiv grew their employee count by 17% last year.
  • BioMotiv currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
N/A81N/AN/A-N/A
#2
$15.2M989%N/A-N/A
#3
$8.4M5429%N/A-N/A
#4
$8.4M5417%N/A-N/A
#5
$10.1M6525%N/A-N/A
#6
N/A272N/AN/A-N/A
#7
$8.1M52225%N/A-N/A
Missing a competitor? Contribute!?
Submit

BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million US and UK initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

54

Number of Employees

$8.4M

Revenue (est)

1

Current Jobs

17%

Employee Growth %

$435.1M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

BioMotiv News

09/03/2019 - Bristol-Myers teams with BioMotiv to build and buy biotechs

Bristol-Myers Squibb has allied with biotech accelerator BioMotiv. The deal sets Bristol-Myers up to found and fund biotechs with BioMotiv ...

09/08/2019 - BioMotiv and Bristol-Myers Squibb Form Strategic Partnership

CLEVELAND & NEW YORK--(BUSINESS WIRE)--BioMotiv, a mission-driven drug development accelerator that advances breakthrough ...

09/03/2019 - Deal Watch: BMS To Tap Early-Stage Breakthroughs In ...

Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis ...

BioMotiv Funding

DateAmountRoundLead InvestorsReference
2012-09-06$21.0MUndisclosedUniversity Hospitals, Harrington FamilyArticle
2013-08-06$46.0MUndisclosedNationwide Mutual Insurance CoArticle
2014-08-15$51.0MUndisclosedArticle
2014-09-29$25.0MUndisclosedTakeda Pharmaceutical Company LimitedArticle
2016-04-15$10.0MUndisclosedCharles River Laboratories International IncArticle
2016-08-09$63.0MUndisclosedArticle